AUROPHARMA Stock Overview
A biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for AUROPHARMA from our risk checks.
Aurobindo Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,249.00 |
| 52 Week High | ₹1,592.00 |
| 52 Week Low | ₹958.50 |
| Beta | 0.59 |
| 11 Month Change | -15.61% |
| 3 Month Change | -16.89% |
| 1 Year Change | 27.90% |
| 33 Year Change | 95.29% |
| 5 Year Change | 190.67% |
| Change since IPO | 1,765.71% |
Recent News & Updates
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Recent updates
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Shareholder Returns
| AUROPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -7.5% | -3.6% | -4.3% |
| 1Y | 27.9% | 43.9% | 27.4% |
Return vs Industry: AUROPHARMA underperformed the Indian Pharmaceuticals industry which returned 43.9% over the past year.
Return vs Market: AUROPHARMA matched the Indian Market which returned 27.4% over the past year.
Price Volatility
| AUROPHARMA volatility | |
|---|---|
| AUROPHARMA Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: AUROPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: AUROPHARMA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 26,015 | Kambam Reddy | www.aurobindo.com |
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams.
Aurobindo Pharma Limited Fundamentals Summary
| AUROPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹725.68b |
| Earnings (TTM) | ₹35.82b |
| Revenue (TTM) | ₹302.95b |
20.3x
P/E Ratio2.4x
P/S RatioIs AUROPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AUROPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹302.95b |
| Cost of Revenue | ₹128.77b |
| Gross Profit | ₹174.18b |
| Other Expenses | ₹138.36b |
| Earnings | ₹35.82b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 61.67 |
| Gross Margin | 57.49% |
| Net Profit Margin | 11.82% |
| Debt/Equity Ratio | 26.2% |
How did AUROPHARMA perform over the long term?
See historical performance and comparison